RY 167.32 0.7952% SHOP 156.84 0.1852% TD 87.295 0.6979% ENB 63.73 0.5522% BN 79.19 -0.1387% TRI 247.45 0.7082% CNQ 44.49 0.9301% CP 103.64 -1.267% CNR 140.22 -0.7573% BMO 140.7 0.8674% BNS 69.62 0.6069% CSU 4745.0 0.3269% CM 83.02 0.6791% MFC 45.15 0.512% ATD 70.57 0.6992% NGT 68.24 1.8052% TRP 70.02 -0.7653% SU 54.83 -0.4177% WCN 275.71 0.9224% L 195.87 1.6292%
Last update at 2025-03-25T18:53:00Z
Is AptarGroup Inc. (ATR) The Best Boring Stock to Buy?
Sun 23 Mar 25, 05:47 PMAptar Recognized with Prestigious 'A' Score on the CDP Climate Change Assessment
Thu 20 Mar 25, 09:00 PMAn Intrinsic Calculation For AptarGroup, Inc. (NYSE:ATR) Suggests It's 30% Undervalued
Wed 26 Feb 25, 10:31 AMZacks Industry Outlook Packaging Corporation of America, Amcor, AptarGroup and Sonoco Products
Thu 13 Feb 25, 10:00 AMAptarGroup Earnings Surpass Estimates in Q4, Increase 27% Y/Y
Mon 10 Feb 25, 03:55 PMInternational Markets and AptarGroup (ATR): A Deep Dive for Investors
Mon 10 Feb 25, 02:15 PMAptarGroup, Inc. Just Beat EPS By 6.8%: Here's What Analysts Think Will Happen Next
Sun 09 Feb 25, 01:20 PMAptarGroup (ATR) Tops Q4 Earnings Estimates
Thu 06 Feb 25, 11:30 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 334.70M | 321.65M | 301.15M | 342.07M | 266.02M |
| Minority interest | -0.26700M | 0.46M | 0.40M | 0.03M | 0.32M |
| Net income | 239.29M | 244.10M | 214.04M | 242.20M | 194.75M |
| Selling general administrative | 544.26M | 551.24M | 500.23M | 454.62M | 429.95M |
| Selling and marketing expenses | - | - | 500.23M | - | - |
| Gross profit | 1163.84M | 1156.68M | 1086.52M | 1041.33M | 951.80M |
| Reconciled depreciation | 233.71M | 234.85M | 220.30M | 194.55M | 171.75M |
| Ebit | 379.27M | 347.35M | 339.50M | 371.69M | 362.48M |
| Ebitda | 617.94M | 605.32M | 581.19M | 592.58M | 534.22M |
| Depreciation and amortization | 238.67M | 257.98M | 241.69M | 220.89M | 171.75M |
| Non operating income net other | - | - | - | 5.87M | 12.38M |
| Operating income | 379.27M | 347.35M | 339.50M | 371.69M | 286.27M |
| Other operating expenses | 2936.38M | 2856.63M | 2563.35M | 2467.57M | 2414.66M |
| Interest expense | 40.83M | 30.28M | 33.24M | 35.49M | 32.63M |
| Tax provision | 95.15M | 78.02M | 87.06M | 99.84M | 71.25M |
| Interest income | 2.70M | 22.60M | 0.96M | 4.17M | 7.06M |
| Net interest income | -38.12700M | -26.61600M | -32.28600M | -31.31500M | -25.57000M |
| Extraordinary items | - | - | - | 0.00000M | 5.40M |
| Non recurring | - | - | - | 20.47M | 63.83M |
| Other items | - | - | - | - | - |
| Income tax expense | 95.15M | 78.02M | 87.06M | 99.84M | 71.25M |
| Total revenue | 3322.25M | 3227.22M | 2929.34M | 2859.73M | 2764.76M |
| Total operating expenses | 777.97M | 786.10M | 720.53M | 649.17M | 601.70M |
| Cost of revenue | 2158.41M | 2070.54M | 1842.82M | 1818.40M | 1812.96M |
| Total other income expense net | -44.56900M | -25.69300M | -38.34300M | -29.62400M | -58.50800M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 239.56M | 243.64M | 214.09M | 242.23M | 194.77M |
| Net income applicable to common shares | 239.29M | 244.10M | 214.04M | 242.20M | 194.75M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 4451.89M | 4203.46M | 4141.36M | 3990.05M | 3562.12M |
| Intangible assets | 283.21M | 315.74M | 362.34M | 344.31M | 291.08M |
| Earning assets | - | - | - | - | - |
| Other current assets | 116.73M | 124.77M | 121.73M | 122.61M | 115.05M |
| Total liab | 2130.59M | 2135.25M | 2156.76M | 2139.27M | 1989.87M |
| Total stockholder equity | 2306.82M | 2053.93M | 1969.41M | 1850.39M | 1571.92M |
| Deferred long term liab | - | - | - | - | 142.61M |
| Other current liab | 404.01M | 393.99M | 320.65M | 331.67M | 293.47M |
| Common stock | 0.72M | 0.71M | 0.70M | 0.69M | 0.69M |
| Capital stock | 0.72M | 0.71M | 0.70M | 0.69M | 0.69M |
| Retained earnings | 2109.82M | 1929.24M | 1789.41M | 1643.83M | 1523.82M |
| Other liab | - | 122.53M | 267.25M | 251.73M | 165.86M |
| Good will | 963.42M | 945.63M | 974.16M | 898.52M | 763.46M |
| Other assets | - | 57.14M | 533.12M | 59.55M | 47.88M |
| Cash | 223.64M | 141.73M | 122.92M | 300.14M | 241.97M |
| Cash and equivalents | - | 141.73M | 122.92M | 300.14M | 241.97M |
| Total current liabilities | 1251.31M | 917.18M | 982.49M | 780.33M | 683.27M |
| Current deferred revenue | 60.51M | 80.11M | 86.95M | 87.05M | 86.82M |
| Net debt | 961.03M | 1033.66M | 1073.73M | 872.73M | 953.73M |
| Short term debt | 458.22M | 122.79M | 289.63M | 117.87M | 110.25M |
| Short long term debt | 458.22M | 122.79M | 285.88M | 117.87M | 110.25M |
| Short long term debt total | 1184.67M | 1175.39M | 1196.65M | 1172.86M | 1195.70M |
| Other stockholder equity | 505.02M | 465.35M | 495.33M | 487.58M | 389.36M |
| Property plant equipment | - | 1402.34M | 1275.88M | 1268.59M | 1087.68M |
| Total current assets | 1549.28M | 1430.29M | 1358.21M | 1368.99M | 1291.24M |
| Long term investments | 49.20M | 52.31M | 59.48M | 50.09M | 8.40M |
| Net tangible assets | - | 792.56M | 995.25M | 607.56M | 1627.19M |
| Short term investments | - | 89.42M | 0.74M | 0.24M | - |
| Net receivables | 695.86M | 676.99M | 671.35M | 566.62M | 558.43M |
| Long term debt | 681.19M | 1052.60M | 907.02M | 1055.00M | 1085.45M |
| Inventory | 513.05M | 486.81M | 441.46M | 379.38M | 375.80M |
| Accounts payable | 328.57M | 320.28M | 285.26M | 243.74M | 192.74M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.34M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -308.73400M | -341.36600M | -316.04100M | -281.70900M | -341.94800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.69M | 0.69M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | 1523.82M |
| Treasury stock | - | - | -421.20300M | -361.58300M | -381.23800M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 69.64M | 411.00M | 533.12M | 523.79M | 419.74M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 2902.61M | 2773.17M | 2783.16M | 2621.06M | 2270.88M |
| Capital lease obligations | 45.27M | 42.95M | 51.75M | 52.21M | 55.28M |
| Long term debt total | - | 1052.60M | 907.02M | 1055.00M | 1085.45M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -295.64200M | -4.93300M | -451.97800M | -3.64600M | -10.77900M |
| Change to liabilities | 55.10M | 52.30M | 65.59M | 0.92M | 11.24M |
| Total cashflows from investing activities | -295.64200M | -457.23900M | -451.97800M | -336.26800M | -735.46100M |
| Net borrowings | 4.99M | 36.95M | -46.85500M | -111.26400M | 41.01M |
| Total cash from financing activities | -162.09600M | -81.51800M | -73.72300M | -197.13500M | -14.87200M |
| Change to operating activities | -28.88500M | -14.15700M | -10.33800M | 14.41M | -4.32600M |
| Net income | 239.56M | 243.64M | 214.09M | 242.23M | 194.77M |
| Change in cash | 19.81M | -182.04500M | 58.00M | -19.85000M | -445.81700M |
| Begin period cash flow | 122.92M | 304.97M | 246.97M | 266.82M | 712.64M |
| End period cash flow | 142.73M | 122.92M | 304.97M | 246.97M | 266.82M |
| Total cash from operating activities | 478.62M | 363.44M | 570.15M | 514.46M | 313.63M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 233.71M | 234.85M | 220.30M | 194.55M | 171.75M |
| Other cashflows from investing activities | 19.97M | -1.18200M | -1.14100M | -90.34600M | -513.43000M |
| Dividends paid | -99.46100M | -98.50900M | -92.65800M | -90.20800M | 82.35M |
| Change to inventory | -60.35400M | -79.96100M | 13.72M | 0.60M | -25.18300M |
| Change to account receivables | -27.93700M | -133.42000M | 4.29M | 21.07M | -79.56000M |
| Sale purchase of stock | -92.12600M | -78.14800M | 68.56M | -86.49700M | -61.69100M |
| Other cashflows from financing activities | 333.41M | -1.71800M | 119.98M | 100.11M | 231.45M |
| Change to netincome | 50.62M | 54.19M | 59.47M | 48.97M | 16.09M |
| Capital expenditures | 315.62M | 307.94M | 252.05M | 247.08M | 211.86M |
| Change receivables | - | - | - | 8.81M | -66.96800M |
| Cash flows other operating | - | - | - | 18.37M | 11.94M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -18.94600M | -436.70500M |
| Change in working capital | -44.99700M | -169.69500M | 76.34M | 28.71M | -62.47700M |
| Stock based compensation | 40.94M | 38.87M | 34.15M | 23.89M | 19.56M |
| Other non cash items | 21.52M | 30.13M | 33.47M | 16.33M | 13.38M |
| Free cash flow | 163.00M | 55.51M | 318.11M | 267.38M | 101.77M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ATR AptarGroup Inc |
-1.37 0.93% | 146.62 | 34.25 | 30.96 | 3.18 | 4.48 | 3.41 | 16.49 |
| ISRG Intuitive Surgical Inc |
7.46 1.47% | 516.04 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
3.66 2.51% | 149.75 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
-0.92 0.32% | 289.58 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
-1.575 0.69% | 227.62 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
AptarGroup, Inc. designs and manufactures a range of drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, beauty, personal care, home care, and food and beverage markets. The company operates through Aptar Pharma, Aptar Beauty, and Aptar Closures segments. It also provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases; elastomer for injectable primary packaging components; and active material science solutions. In addition, the company offers dispensing pumps, closures, elastomeric components, and aerosol valves to the digital health solutions. It primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
265 Exchange Drive, Crystal Lake, IL, United States, 60014
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephan B. Tanda | Pres, CEO & Exec. Director | 1965 |
| Mr. Robert W. Kuhn | Exec. VP & CFO | 1962 |
| Mr. Gael Touya | Pres of Aptar Pharma | 1970 |
| Mr. Marc Prieur | Pres of Aptar Beauty + Home | 1966 |
| Ms. Xiangwei Gong | Pres of Aptar Asia | 1970 |
| Mr. Matthew DellaMaria | Sr. VP of Investor Relations & Communications | NA |
| Ms. Kimberly Y. Chainey | Exec. VP, Chief Legal Officer & Corp. Sec. | 1976 |
| Ms. Shiela Pallerne Vinczeller | Chief HR Officer | 1964 |
| Mr. Heidi Tlili | Pres of Aptar Food + Beverage | 1975 |
| Mr. Stephan B. Tanda | President, CEO & Executive Director | 1965 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA
AU
UK
US
NZ
Please wait processing your request...